Tuning protein folding in lysosomal storage diseases: the chemistry behind pharmacological chaperones

被引：69
|
作者：
Pereira, David M. [1 ]
Valentao, Patricia [1 ]
Andrade, Paula B. [1 ]
机构：
[1] Univ Porto, REQUIMTE LAQV, Lab Farmacognosia, Dept Quim,Fac Farm, Rua Jorge Viterbo Ferreira 228, P-4050313 Oporto, Portugal
来源：
CHEMICAL SCIENCE | 2018年 / 9卷 / 07期
关键词：
TYPE-1; GAUCHER-DISEASE; GLOBOID-CELL LEUKODYSTROPHY; ENZYME REPLACEMENT THERAPY; ACID-BETA-GLUCOSIDASE; KRABBE-DISEASE; CHEMICAL CHAPERONES; ALPHA-GALACTOSIDASE; MOLECULAR-BASIS; FABRY DISEASE; ENDOPLASMIC-RETICULUM;
D O I：
10.1039/c7sc04712f
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Misfolding of proteins is the basis of several proteinopathies. Chemical and pharmacological chaperones are small molecules capable of inducing the correct conformation of proteins, thus being of interest for human therapeutics. The most recent developments in medicinal chemistry and in the drug development of pharmacological chaperones are discussed, with focus on lysosomal storage diseases.
引用
收藏
页码：1740 / 1752
页数：13
相关论文
共 35 条
  • [1] Pharmacological Chaperones as Therapeutics for Lysosomal Storage Diseases
    Boyd, Robert E.
    Lee, Gary
    Rybczynski, Philip
    Benjamin, Elfrida R.
    Khanna, Richie
    Wustman, Brandon A.
    Valenzano, Kenneth J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (07) : 2705 - 2725
  • [2] Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics
    Parenti, Giancarlo
    EMBO MOLECULAR MEDICINE, 2009, 1 (05) : 268 - 279
  • [3] Extracellular chaperones in lysosomal storage diseases
    Inci, Asli
    Dokmeci, Serap
    MOLECULAR GENETICS AND METABOLISM, 2025, 145 (01)
  • [4] Chemical and Pharmacological Chaperones: Application for Recombinant Protein Production and Protein Folding Diseases
    Rajan, Rahul S.
    Tsumoto, Kouhei
    Tokunaga, Masao
    Tokunaga, Hiroko
    Kita, Yoshiko
    Arakawa, Tsutomu
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (01) : 1 - 15
  • [5] Pharmacological chaperones for the treatment of lysosomal storage disorders.
    Flanagan, J. J.
    Khanna, R.
    Powe, A. C.
    Wu, X.
    Benjamin, E. R.
    Liang, W.
    Soska, R.
    Tang, K.
    Pelligrino, L.
    Lun, Y.
    Sitaraman, S.
    Palling, D.
    Wustman, B. A.
    Valenzano, K. J.
    Do, H. V.
    Lockhart, D. J.
    MOLECULAR GENETICS AND METABOLISM, 2008, 93 (03) : 249 - 249
  • [6] Allosteric, non-inhibitory pharmacological chaperones for the treatment of lysosomal diseases
    Roberts, Richard
    Rodriguez-Pascau, Laura
    Maria Garcia, Ana
    Cubero, Elena
    Pizcueta, Pilar
    Delgado, Aida
    Reves, Marc
    Perez, Natalia
    Ruano, Ana
    Aymami, Joan
    Higaki, Katsumi
    Grinberg, Daniel
    Vilageliu, Lluisa
    Martinell, Marc
    Barril, Xavier
    MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) : S115 - S116
  • [7] A Drug Discovery Platform to Identify Chaperones for Lysosomal Storage Diseases
    Puhl, Ana C.
    Klein, Jennifer J.
    Vignaux, Patricia A.
    Minerali, Eni
    Foil, Daniel
    Zorn, Kimberley M.
    Ekins, Sean
    NEUROTHERAPEUTICS, 2020, 17 (03) : 1313 - 1313
  • [8] Pharmacological chaperone therapy for lysosomal storage diseases
    Parenti, Giancarlo
    Moracci, Marco
    Fecarotta, Simona
    Andria, Generoso
    FUTURE MEDICINAL CHEMISTRY, 2014, 6 (09) : 1031 - 1045
  • [9] Chemical chaperones: A pharmacological strategy for disorders of protein folding and trafficking
    Perlmutter, DH
    PEDIATRIC RESEARCH, 2002, 52 (06) : 832 - 836
  • [10] Chemical chaperones: A pharmacological strategy for disorders of protein folding and trafficking
    Perlmutter D.H.
    Pediatric Research, 2002, 52 (6) : 832 - 836
1234